This trial seeks to evaluate whether ketamine can improve outcomes for people with opioid use disorder who are also struggling with depression.
- Opioid Use Disorder
5 Primary · 3 Secondary · Reporting Duration: One year
Side Effects for
1 Treatment Group
1 of 1
6 Total Participants · 1 Treatment Group
Primary Treatment: Ketamine Hydrochloride · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18 - 65 · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is this research protocol available to participants at present?
"Affirmative. According to clinicaltrials.gov, this medical trial is actively seeking participants as of October 7th 2022 - the date that it was last updated. The initial posting on April 4th 2022 highlighted 6 enrollees needed at a single institution." - Anonymous Online Contributor
Is Ketamine Hydrochloride a viable option for individuals with no long-term risks?
"The safety of Ketamine Hydrochloride is rated as 2 since there has been some evidence to suggest it is safe but no data demonstrating its efficacy." - Anonymous Online Contributor
Is this clinical investigation open to elderly participants?
"As per the eligibility requirements, only individuals aged 18 or older but no more than 65 can enroll in this clinical trial." - Anonymous Online Contributor
How many research subjects are engaged in this investigation?
"Affirmative. Per the information on clinicaltrials.gov, this medical trial is actively searching for participants to join their research endeavour. This project was initially posted online on April 4th 2022 and has been freshly updated as of October 7th 2022. The team are seeking 6 volunteers at one facility in particular." - Anonymous Online Contributor
Do I qualify to partake in this experiment?
"This clinical trial is accepting 6 individuals, aged 18 to 65 years old, diagnosed with melancholia. Besides meeting the age criteria, potential participants must also meet certain prerequisites including: a history of illicit opioid use according to National Health Service (NHS) prescreening; fulfilment of DSM-5/ICD-10 criteria for moderate-to-severe opioid or heroin use disorder; acceptance into methadone maintenance care for treatment of opioid or heroin use disorder; 10 points on the PHQ-9 scale at screening stage and no prior sustained experience/dependence on ketamine as per responses in the respective questionnaire." - Anonymous Online Contributor